IP Library Granted Patent US 11,439,132
Granted Patent B2
US 11,439,132 · App. 17/089,479 · Granted Sep 13, 2022

Humanized transgenic animal

Inventors: Yuelei Shen (Beijing, CN); Chaoshe Guo (Beijing, CN); Yanan Guo (Beijing, CN); Yang Bai (Beijing, CN); Rui Huang (Beijing, CN); Lei Zhao (Beijing, CN); Xiaofei Zhou (Beijing, CN); Meiling Zhang (Beijing, CN); Jiawei Yao (Beijing, CN)
Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
A01K67/0278C07K14/525C07K14/54C07K14/7155A01K2217/072A01K2227/105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,439,132
App. No.
17/089,479
Granted
Sep 13, 2022
Kind
B2
Abstract

Provided are a humanized transgenic non-human animal, especially a rodent, in particular a transgenic mouse containing a human interleukin 17A (IL-17A) gene, a human gene 17RA (IL-17RA) and/or a human TNF-alpha gene, and a preparation method therefor and the use thereof.

Claims (17)

1. A genetically-modified, non-human animal whose genome comprises a sequence encoding a humanized IL-17RA protein at an endogenous IL-17RA gene locus, wherein the sequence encoding the humanized IL-17RA protein is operably linked to an endogenous IL-17RA regulatory element at an endogenous IL-17RA gene locus, wherein the animal comprises a replacement of a part of exon 2, exons 3-10 and a part of exon 11 of the endogenous IL-17RA gene, with a part of exon 2, exons 3-10 and a part of exon 11 of a human IL-17RA gene, wherein the non-human animal detectably expresses the humanized IL-17RA protein on the surface of spleen cells, and the humanized IL-17RA protein comprises an amino acid sequence that is at least 95% identical SEQ ID NO: 39.

2. The animal of claim 1 , wherein the humanized IL-17RA protein comprises SEQ ID NO: 39.

3. The animal of claim 1 , wherein the genome of the animal further comprises a sequence encoding a human IL-17A protein, wherein the sequence encoding the human IL-17A protein is operably linked to an endogenous 5′UTR at an endogenous IL-17A gene locus.

4. The animal of claim 3 , wherein the human IL-17A protein comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 4.

5. The animal of claim 3 , wherein the human IL-17A protein comprises SEQ ID NO: 4.

6. The animal of claim 3 , wherein the animal expresses the human IL-17A protein.

7. The animal of claim 3 , wherein the animal is a rodent.

8. The animal of claim 3 , wherein the animal is a mouse.

9. The animal of claim 3 , whose genome comprises a replacement of a sequence encoding an endogenous IL-17A protein with a sequence encoding the human IL-17A protein.

10. The animal of claim 3 , wherein the animal further comprises a sequence encoding a human TNF-α protein.

11. A method for making a genetically-modified non-human animal, comprising:

(a) replacing in a fertilized egg or an embryonic stem cell, at an endogenous IL-17RA gene locus, a part of exon 2, exons 3-10, and a part of exon 11 of endogenous IL-17RA gene with a part of exon 2, exons 3-10 and a part of exon 11 of a human IL-17RA gene;

(b) transplanting the fertilized egg of step (a) into a female non-human animal or transplanting the embryonic stem cell of step (a) into a blastocyst, which is then transferred into a female non-human animal; and

(c) obtaining a genetically-modified, non-human animal, wherein the non-human animal has genome that comprises a sequence encoding a humanized IL-17RA protein that is operably linked to an endogenous IL-17RA regulatory element at an endogenous IL-17RA gene locus.

12. The method of claim 11 , wherein the humanized IL-17RA protein comprises an amino acid sequence that is at least 95% identical SEQ ID NO: 39.

13. The method of claim 11 , wherein the humanized IL-17RA protein comprises SEQ ID NO: 39.

14. The method of claim 11 , wherein the non-human animal detectably expresses the humanized IL-17RA protein on the surface of spleen cells.

Assignments (2)
CHANGE OF NAME Recorded Jan 22, 2021
From: BEIJING BIOCYTOGEN CO., LTD
To: BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Reel/Frame 055087/0015 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2020
From: SHEN, YUELEI; GUO, CHAOSHE; GUO, YANAN; BAI, YANG; HUANG, RUI; ZHAO, LEI; ZHOU, XIAOFEI; ZHANG, MEILING; YAO, JIAWEI
To: BEIJING BIOCYTOGEN CO., LTD.
Reel/Frame 054303/0465 →
Priority Claims (2)
CN 201910044180.6 · Jan 17, 2019 · national
CN 201910616231.8 · Jul 9, 2019 · national
Continuity (2)
Continuation PCTCN2020072714 · Jan 17, 2020
Related Publication 20210068379A1 · Mar 11, 2021